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Cardiomyocyte size in the healthy heart is in part determined by the level of circulating thy-
roid hormone (TH). Higher levels ofTH induce ventricular hypertrophy, primarily in response
to an increase in hemodynamic load. Normal cardiac function is maintained in this form
of hypertrophy, whereas progressive contractile dysfunction is a hallmark of pathological
hypertrophy. MicroRNAs (miRNAs) are important modulators of signal-transduction path-
ways driving adverse remodeling. Because little is known about the involvement of miRNAs
in cardiac TH action and hypertrophy, we examined the miRNA expression profile of the
hypertrophied left ventricle (LV) using a mouse model of TH-induced cardiac hypertrophy.
C57Bl/6J mice were rendered hypothyroid by treatment with propylthiouracil and were
subsequently treated for 3 days with TH (T3) or saline. T3 treatment increased LV weight
by 38% (p<0.05). RNA was isolated from the LV and expression of 641 mouse miRNAs
was determined using Taqman Megaplex arrays. Data were analyzed using RQ-manager
and DataAssist. A total of 52 T3-regulated miRNAs showing a >2-fold change (p<0.05)
were included in Ingenuity Pathway Analysis to predict target mRNAs involved in cardiac
hypertrophy.The analysis was further restricted to proteins that have been validated as key
factors in hypertrophic signal transduction in mouse models of ventricular remodeling. A
total of 27 mRNAs were identified as bona fide targets. The predicted regulation of 19%
of these targets indicates enhancement of physiological hypertrophy, while 56% indicates
suppression of pathological remodeling. Our data suggest that cardiac TH action includes
a novel level of regulation in which a unique set of TH-dependent miRNAs primarily sup-
presses pathological hypertrophic signaling. This may be relevant for our understanding
of the progression of adverse remodeling, since cardiac TH levels are known to decrease
substantially in various forms of pathological hypertrophy.
Keywords: thyroid hormone, hyperthyroidism, microRNA, pathway analysis, physiological hypertrophy, patholog-
ical hypertrophy
INTRODUCTION
An increase in the hemodynamic load placed on the heart induces
cardiomyocyte hypertrophy. The resulting increase in ventricu-
lar mass is aimed at normalizing wall stress and maintaining
cardiac output. In the context of chronic pressure and/or vol-
ume overload, such as in hypertension, aortic stenosis, valvular
disease, or following myocardial infarction, the initially adaptive
response is associated with progressive contractile dysfunction and
heart failure (1). This pathological remodeling is characterized by
distinct changes in cardiac gene expression, increased cardiomy-
ocyte apoptosis, and fibrosis. Typical phenotypic changes include
a shift in expression from the fast contractile protein myosin
heavy chain α (Myh6) to the slow β isoform (Myh7 ) (2), reduced
expression of sarcoplasmic reticulum Ca2+-ATPase (Serca2a) (2,
3), and increased expression of fetal genes [e.g., α-skeletal actin,
atrial natriuretic peptide (Anp), B-type natriuretic peptide (Bnp),
deiodinase type III (Dio3) (4–6)].
In contrast, cardiac hypertrophy in response to increased lev-
els of circulating thyroid hormone (TH) (hyperthyroidism) is not
associated with adverse remodeling or impairment of contractility
in both animals and human beings (7–9), in spite of the chronically
increased hemodynamic load, which also in this case is the princi-
pal trigger of cardiomyocyte growth (10, 11). TH-induced remod-
eling is, therefore, considered physiological and is similar to physi-
ological ventricular hypertrophy induced by pregnancy or chronic
exercise training, and is equally reversible (12–14).
The distinction between stimuli and the related signal-
transduction pathways that cause either pathological or phys-
iological hypertrophy has not been without discussion. It has
been presumed that the duration of the stimulus, i.e., chronic
or intermittent, is the key difference determining the two forms
of hypertrophy. Nevertheless, studies using intermittent pressure
overload showed that although the resulting hypertrophy appeared
to be adaptive, the cellular characteristics already showed all fea-
tures of pathological remodeling (15). This suggests that certain
aspects of the different stimuli and down-stream processes deter-
mine the phenotype of hypertrophy, rather than the duration of
the exposure to the stimuli (16).
Gain- and loss-of-function studies have delineated numerous
signal-transduction pathways which relay the various neurohu-
moral and mechanical signals that drive cardiac hypertrophy [see
Ref. (16) for an extensive review]. There is considerable overlap
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and cross-talk between these pathways and although some path-
ways appear to mediate physiological, and others, pathological
hypertrophy, the mechanisms underlying development of either
one of these distinct phenotypes in response to chronic overload
are not clear (16). In the case of TH, some effects of pathologi-
cal signaling will be countered by direct transcriptional regulation
of genes such as Myh6, Myh7, and Serca2a (7, 17), mediated by
the TH receptors α1 or β1 (18). Both receptors are capable of
mediating the transcriptional T3 effect, and they are also impli-
cated in the non-genomic T3 effect involving stimulation of the
phosphoinositide 3-kinase [PI3K (p110α)]-Akt pathway (19–21).
However, additional mechanisms are expected to account for the
full suppression of adverse remodeling.
Recent studies have shown an important role for microRNAs
(miRNAs) in the regulation of cardiac gene expression by virtue
of their ability to induce degradation of specific target mRNAs
or reduce the efficiency of translation (22, 23). Although miRNAs
are generally considered to fine-tune gene expression, critical roles
of individual miRNAs have been established in various aspects
of pathological cardiac hypertrophy (22–25). For example, miR-
208a is required for overload-induced pathological remodeling,
including cardiomyocyte hypertrophy, Myh isoform switching,
and fibrosis (26, 27). Furthermore, forced expression of miR-
208a induces pathological remodeling (27), whereas blocking of
miR-208a attenuates hypertension-induced cardiac dysfunction
(28).This miRNA is encoded in an intron of the Myh6 gene, which
is transcriptionally stimulated by TH. Consequently, and per-
haps counter intuitively, expression of this “pathological” miRNA
is increased in hyperthyroidism (27, 29). Little else is known
about the TH-dependency of miRNA expression in the heart,
despite the obvious potential of miRNA-mediated effects. How-
ever, studies in liver and skeletal muscle (30, 31) have identified
a number of TH-responsive miRNAs, which are also known to
play a role in remodeling adult cardiomyocytes and differentiating
cardiomyocyte progenitor cells (32–35).
As a first step in elucidating a role of miRNAs in cardiac TH
action, we set out to identify TH-responsive cardiac miRNAs using
a mouse model of physiological hypertrophy induced by TH. To
increase the sensitivity and to limit long-term secondary effects,
TH-deficient mice were treated for 3 days with T3, the active form
of TH. Target analysis of the 52 differentially regulated miRNAs
indicated limited potentiation of pathways involved in physiologi-
cal hypertrophy, but a marked suppression of pathways associated
with pathological hypertrophy. Our data suggest that cardiac TH
action includes a novel level of regulation in which a unique set
of TH-dependent miRNAs suppresses pathological hypertrophic
signaling.
MATERIALS AND METHODS
ANIMALS
Two groups of six male C57BL/6 mice (10–12 weeks, Charles
Rivers) were used. Both groups were allowed ad libitum access
to food containing PTU (Teklad+ 0.15% propylthiouracil) for
44 days to induce hypothyroidism. Six mice were injected (IP) with
a supra-physiological dose of 5µg T3 in 20µl saline at day 42, 43,
and 44 (corresponding to 0.21–0.24µg T3/g BW); the remaining
six hypothyroid mice were injected with 20µl saline. Animals were
sacrificed at day 45. The heart was excised and left and right ven-
tricle (LV, RV) and septum were dissected, weighed, immediately
frozen in liquid nitrogen, and stored at −80°C. Tibia length was
determined for normalization purposes. Plasma T3 levels were
determined by AccuBind ELISA kits (Monobind Inc., Lake Forest,
CA) according to the manufacturer’s instructions. Animals were
housed individually and all experiments complied with the Guide
for Care and Use of Laboratory Animals of the National Institutes
of Health (NIH Publication no. 86-23, revised 1996) and were
approved by the Institutional Animal Care and use Committees of
VU University Medical Center Amsterdam.
RNA ISOLATION
Total RNA was isolated from approximately 20 mg LV using the
mirVana Paris isolation kit (Ambion, Foster City, CA). To improve
cell lysis, frozen samples were sliced into 10µm sections using a
cryostat. The tissue sections were dissolved in 2 ml cell disruption
buffer. Three aliquots of 500µl lysate were transferred to Eppen-
dorf tubes and 500µl of 2× denaturation solution, containing
guanidinium thiocyanate, was added to each tube to prevent RNA
degradation by cellular ribonucleases. Subsequently, an equal vol-
ume of acid-phenol:chloroform was added to separate RNA from
DNA and protein (36). The aqueous phase was transferred to a
fresh tube. To make sure there was no DNA or protein left, we
repeated the previous step. Next, 1.25 volumes of 100% ethanol
was added before each extract was transferred onto an individual
filter cartridge, centrifuged, and washed. The bound RNA frac-
tion was pretreated with DNAseI (Qiagen, Venlo, the Netherlands)
before 105µl elution buffer was added to each filter cartridge to
collect the total RNA fraction. It should be noted that the capacity
of the filter is limited, requiring the use of three cartridges per sam-
ple. RNA concentration and quality were measured either with the
Nanodrop1000 (Thermo Scientific, Wilmington, DE) or the 2100
Bioanalyzer (Agilent Technologies, Santa Clara, CA). Samples were
stored at−80°C, at which temperature miRNAs are stable (37).
QUANTITATIVE REAL-TIME PCR
To analyze mRNA levels of the TH-regulated myosin heavy
chains (Myh6, Myh7 ), 10µl DNaseI-treated total RNA was
transcribed to cDNA using Cloned AMV first strand cDNA
synthesis (Invitrogen, Carlsbad, CA, USA). RNA concentra-
tion was adjusted to 12.5 ng/µl. Quantitative real-time poly-
merase chain reaction (qPCR) was performed using MESA
GREEN qPCR MasterMix Plus for SYBR assay (Euro-
gentec, Seraing, Belgium) and specific primers (38) for
Myh6 (sense: 5′-GACCAGGCCAATGAGTACCG-3, antisense:
5′-GCCTAGCCAACTCCCCGTTC-3′) and Myh7 (sense: 5′-
CGCTCCACGCACCCTCACTT-3′, antisense: 5′-GTCCATCACC
CCT GGAGAC-3′) in an Applied Biosystems model 7700
(Applied Biosystems, Foster City, CA). Expression levels of
Hprt (sense: 5′-TCCCTGGTTAAGCAGTACAGCC-3′, antisense:
5′-CGAGAGGTCCTTTTCACCAGC-3′) were used for nor-
malization. For comparison of the relative gene expression
[2(Ct HPRT – Ct target)] of the two groups, a two-tailed Student t -test
was performed to calculate p values.
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Table 1 | Effects of short-termT3 treatment on BW, HW, and plasmaT3
levels.
HO HOT3
Anatomic data
Body weight day 0 (g) 22.1±0.5 22.1±0.6
Body weight day 44 (g) 22.7±0.4 22.6±0.5
Total heart weight/TL (mg/cm) 41.3±1.1 58.1±0.6*
LV weight/TL (mg/cm) 24.0±1.4 33.1±1.2*
Thyroid hormone status
T3 levels (nM) 0.1±0.1 47.5±4.2*
Twelve mice were allowed ad libitum access to food containing PTU for
44 days. Six randomly chosen mice were injected with T3 at day 42, 43, and
44. Controls received vehicle. Mice were sacrificed at day 45. Body weight
remained unchanged during the experiment. Total heart weight increased by
41%, and LV weight increased by 38%. T3 treatment resulted in 475 times
higher T3 levels in the hyperthyroid mice. Heart weight was corrected for TL,
tibia length; HO, hypothyroid; HOT3, hyperthyroid. Values are means±SEM;
*p< 0.05.
MicroRNA EXPRESSION ANALYSIS
TaqMan miRNA Megaplex array (Applied Biosystems, Foster City,
CA) was used to analyze miRNAs expression profiles. To syn-
thesize cDNA, 3µl RNA was added to 4.5µl of RT-PCR reac-
tion mix consisting of specially designed Megaplex RT primers
(Rodent pool A or B, v3), dNTPs, MultiScribe reverse transcrip-
tase, 10× reaction buffer, MgCl2, and RNase inhibitor. Subse-
quently, the mixture was subjected to 40 cycles for 2 min at 16°C,
for 1 min at 42°C, and for 1 s at 50°C, followed by 5 min at
85°C and cooling to 4°C. A pre-amplification was performed to
increase the cDNA quantity, thereby improving the sensitivity of
miRNA detection (39). The pre-amplification mixture consisted
of 2.5µl RT product, 12.5µl TaqMan PreAmp master mix, and
Megaplex PreAmp primers. The mixture was incubated for 10 min
at 95°C, 2 min at 55°C, 2 min at 72°C followed by 12 cycles of
15 s 95°C and 4 min at 60°C, inactivated for 10 min at 99.9°C,
and cooled down to 4°C. Each product was diluted by adding
75µl 0.1× TE (pH 8.0). After 9µl diluted pre-amplified target
cDNA was added to 450µl 2× TaqMan Universal master mix
(w/o amperase) and 441µl nuclease free water, 100µl mixture
FIGURE 1 |The effects ofT3 treatment on Myh-isoform expression and
corresponding miRNAs. RNA was isolated from the LV of six hypothyroid
(HO) and six hyperthyroid (HOT3) mice. The low Myh6 [(A), open bar] and
high Myh7 mRNA levels [(B), open bar] are indicative of the low cardiac T3
state in the hypothyroid animals. The TH-responsiveness of both genes was
evident from the shift in expression of Myh6 [(A), solid bar] and Myh7
[(B), solid bar] as a result of T3 treatment. MiRNAs 208a and 208b are located
within Myh6 and Myh7. The expression pattern of miR-208a (C) and
miR-208b (D) in these conditions is similar to the pattern of their host genes.
HO set to 1, values are means±SEM; *p<0.05.
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FIGURE 2 | Continued
FIGURE 2 | Continued
T3 treatment for 3 days revealed a unique miRNA profile in the
hypertrophied LV. Expression data of 641 known mouse miRNAs were
obtained with TaqMan Megaplex arrays (v3. A and B, rodent) and analyzed
using RQ-manager (v1.2) and DataAssist (v3.0). The depicted heat map
represents a unique profile of 52 differentially expressed miRNAs after
3 days of T3 treatment with a FC>± 2 and a p-value<0.05. Blue, low; red,
high.
per lane was added to the TaqMan array card. The qPCR was
performed on a 7900HT system with TLDA arrays. MammU6
and snoRNA202 were the most stable miRNAs and, therefore,
chosen as endogenous controls. Comparative threshold (Ct) val-
ues were analyzed by SDS software v2.3 before being exported to
RQ-manager v1.2 (Applied Biosystems). Data were next exported
to DataAssist v3.0 (Applied Biosystems) for statistical analyses.
MiRNAs with Ct’s above 38 were designated “not-expressed” and
excluded from the analyses. Data were only considered when
expression of a particular miRNA was observed in at least five mice
of each group. A two-tailed Student t -test was used for two-group
comparisons.
PREDICTION OF miRNA TARGETS
To obtain an overview of the predicted miRNA targets and their
role in biological processes, we analyzed significantly differen-
tially regulated miRNAs with Ingenuity Systems Pathway Analysis
software (IPA, Ingenuity Systems, www.ingenuity.com). Briefly,
after analyzing the expression of all the detected miRNAs using
DataAssist, a list of significantly differentially regulated miR-
NAs was uploaded to IPA. The uploaded miRNAs were analyzed
using the microRNA Target Filter to find experimentally validated
miRNA targets from Tarbase and miRecords, as well as highly pre-
dicted miRNA-mRNA pairing from Targetscan. Additionally, IPA
includes peer-reviewed biological literature describing miRNA–
target interactions. We focused only on miRNAs that were up- or
downregulated by at least a fold change (FC) of >±2 and p-value
of <0.05. Targets expressed in heart tissue were used for further
in silico analysis.
RESULTS
LEFT VENTRICULAR HYPERTROPHY INDUCED BY T3 TREATMENT
Hypothyroidism was induced using the established 40-day pro-
tocol of ad libitum access to food containing PTU (40). Indica-
tive of the low plasma T3 levels and in agreement with earlier
studies, growth was arrested in these animals (Table 1) (40).
T3 treatment for three consecutive days resulted in a ~475-fold
increase of plasma T3. Cardiac hypertrophy was evident from
a 41% increase in total heart weight, and a 38% increase in
weight of the LV free wall, which was used in all further analyses
(Table 1).
A total RNA fraction was isolated from approximately 20 mg
LV tissue. Expression analysis of the TH-regulated Myh6 and
Myh7 genes indicated the low cardiac T3 state in the hypothy-
roid animals, showing low Myh6 and high Myh7 mRNA levels
(2). The TH-responsiveness of both genes was evident from the
shift in expression of Myh6 and Myh7 as a result of T3 treatment
(Figures 1A,B).
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ALTERED miRNA EXPRESSION PROFILE INDUCED BY T3 TREATMENT
Using a platform based on stem-loop primers, we observed 45
significantly upregulated and 104 significantly downregulated
miRNAs as a result of T3 treatment (Table S1 in Supplementary
Material). Among these miRNAs, 208a and 208b are examples
of miRNAs known to be up- and downregulated, respectively, in
response to increasing TH levels (27, 29). Both miR-208a and 208b
followed the expression of their corresponding host genes Myh6
and Myh7, respectively (Figures 1C,D).
ANALYSIS OF POTENTIAL TARGET mRNAs OF T3-REGULATED miRNAs
Of the total of 149 differentially regulated miRNAs, 52 met the cri-
teria of at least a twofold increase or a 50% decrease and having a
p-value< 0.05. This group of 52 forms a unique signature of miR-
NAs differentially regulated after 3 days of T3 treatment (Figure 2).
To test for potential target mRNAs, in silico target prediction was
performed using a web-based entry tool, IPA. Thirty-one out of
the 52 miRNAs had targeting information available in the Inge-
nuity database and could be used in the IPA analysis (Table S2
in Supplementary Material). The predicted interaction between
miRNA and its target mRNA was based on sequence homology
of the miRNA seed region and the target sequence present in the
3′ UTR of the mRNA. The analysis was furthermore restricted to
mRNAs known to be expressed in heart tissue. In this way, a total
of 3274 mRNAs were identified as potential targets of the group of
31 miRNAs. An IPA “core” analysis was subsequently performed to
relate the predicted target mRNAs to known biological functions
and processes. This revealed that the predicted target mRNAs
were significantly represented in “cardiovascular system develop-
ment and function,” “cell death and survival,” “cellular growth
and proliferation,” “energy metabolism,” and “lipid metabolism”
(Figure 3).
PATHWAY ANALYSIS OF POTENTIAL TARGET mRNAs INVOLVED IN
T3-INDUCED CARDIAC HYPERTROPHY
We next focused our analyses on target mRNAs encoding proteins
which have been shown to be critical components of hyper-
trophic signaling pathways, i.e., the IGF-1-, NFAT-, Ca2+-, GPCR-,
JAK/STAT-, PI3K/Akt-, ERK/MAPK-, and TH-signaling pathways
(16) and which have been validated in mouse models of patholog-
ical and/or physiological hypertrophy. Analysis was furthermore
limited to mRNAs that are solely targeted by either up- or down-
regulated miRNAs, so that the effect of miRNA regulation on the
expression of these signaling components is unequivocal. This
approach resulted in 27 candidates (Figure 4). In depth analy-
ses using IPA and additional literature searches revealed that
the predicted regulation of 5 of these targets (19%) results in
enhancement of physiological hypertrophy, whereas regulation of
15 of these targets (56%) results in suppression of pathological
remodeling (Table 2).
FIGURE 3 | Clustering of target mRNAs into biological groups.
Clustering of predicted target mRNAs into biological groups was
performed with IPA. Predicted target mRNAs were represented in
processes involved in “cardiovascular system development and
function,” “cell death and survival,” “cellular growth and
proliferation,” “energy metabolism,” and “lipid metabolism.” Numbers
indicate the number of target mRNAs involved in the corresponding
process.
www.frontiersin.org October 2014 | Volume 5 | Article 171 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Janssen et al. TH-regulated miRNAs suppress hypertrophy
FIGURE 4 | Predicted target mRNAs involved in signature
pathways of cardiac hypertrophy. Of the 2312 mRNAs that were
targeted by either up- or downregulated miRNAs, 27 bona fide targets
were found to be involved in cardiac hypertrophy. The presented
molecules are members of at least one of the eight selected
signature transduction pathways involved in the development of
cardiac hypertrophy. Red, the corresponding miRNA was shown to be
downregulated in HOT3, which resulted in a predicted upregulation of
its target mRNA; green, the corresponding miRNA was shown to be
upregulated in hyperthyroid LV, which resulted in a predicted
downregulation of its target mRNA. “*” Indicates target mRNAs
involved in physiological hypertrophy.
DISCUSSION
In this paper, we describe an unbiased in silico approach to ana-
lyze differentially expressed cardiac miRNAs in the physiologically
hypertrophied mouse heart as a result of T3 treatment. Our data
show that next to the known extra-cardiac effects of T3 on the heart
due to an increase in hemodynamic load (10, 11), and modula-
tion of TH-regulated genes (2, 3), a T3-dependent miRNA profile
is expressed which is predicted to primarily suppress pathways
involved in pathological hypertrophy, with some enhancement of
pathways involved in physiological hypertrophy.
We chose to use hypothyroid mice treated for only 3 days with
T3 to optimize the identification of T3-responsive miRNAs. The
reciprocal regulation of the TH-regulated myosin genes, Myh6
and Myh7, and the 41% increase in heart weight are in line with
previous findings (14, 66, 67). Earlier studies established that the
T3-induced increase in heart weight is caused by an increase in
cell size and is not accompanied by fibrotic deposition (68, 69).
Some of the observed changes in the miRNA expression profile
of the hypertrophied LV, following T3 treatment, also confirmed
earlier results. The observed reciprocal expression of the miR-
NAs 208a and 208b, which originate from introns of Myh6 and
Myh7, respectively, has been reported before (27, 29). As already
mentioned in the Section “Introduction,” expression of miR-208a
has been implicated in the development of pathological hypertro-
phy. Mir-208a targets the Thyroid Hormone Receptor Associated
Protein 1 (Thrap1) (26, 27, 70), which is a component of the
TH-receptor/co-factor complex that mediates transcriptional reg-
ulation of T3-dependent genes (26,27,71,72). Increased miR-208a
expression is, therefore, expected to decrease T3 action, because
Thrap1 expression will be decreased. However, our data suggest
that in the presence of high levels of T3, the effect of miR-208a
on the efficiency of T3-regulated gene expression and patholog-
ical signaling is minimal, since it does not prevent T3-induced
gene expression nor does it result in a pathological phenotype
under this condition. Also, in line with earlier results, the cardiac
miRNAs, miR-206 and miR-1, which were shown to be downreg-
ulated by TH in liver and skeletal muscle (30, 31), were found to
be suppressed by T3 treatment in the present study.
Furthermore, our results are consistent with data obtained
using a model of exercise-induced cardiac hypertrophy (73), show-
ing a significant downregulation of miR-26b, 27a, and 143 after
7 days of exercise. Moreover, a trend toward downregulation of
miR-195 and 499 was observed in that study, where we found
significant downregulation of both miRNAs after 3 days of T3
treatment. Exercise-induced physiological cardiac growth has been
considered similar to TH-induced physiological hypertrophy (16),
and our data suggest that this similarity may involve regulation by
miRNAs.
In-depth analysis of our set of 149 differentially expressed miR-
NAs revealed 52 with a FC>±2 and a p-value< 0.05, which
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Table 2 | Predicted interaction ofT3-induced miRNA expression and hypertrophic signaling pathways.
mRNA miR Induction Reference
UPREGULATEDTARGET MRNAS INVOLVED IN PATHOLOGICAL HYPERTROPHY
Map2k3 590 Dominant negative Map2k3 increases hypertrophy TAC, AngII, Iso (41)
Map2k6 29b Dominant negative Map2k6 increases hypertrophy TAC, AngII, Iso (41)
Slc8a1 721 Reduced levels of Slc8a1 caused hypertrophy TAC (42)
DOWNREGULATEDTARGET MRNAS INVOLVED IN PATHOLOGICAL HYPERTROPHY
Agtr2 539 Chronic loss of Agtr2 attenuates left ventricular hypertrophy AngII (43)
Camk2d 539, 7b Inhibition prevents maladaptive remodeling TAC, Iso (44, 45)
Ctgf 124, 212, 18a Inhibition attenuates LV remodeling in pressure overload-induced heart failure TAC, AngII (46, 47)
Ep300 212 Specific reduction of Ep300 content or activity diminishes stress-induced hypertrophy TAC (48, 49)
Grb2 124, 141 Grb2+/− mice showed a reduced hypertrophic response in response to overload TAC (50)
Hif-1α 18a Deletion of Hif-1α prevents hypertrophy TAC (51)
Htr2a 34c Blockade of Htr2a has a beneficial effect on the development of hypertrophy TAC (52)
Ikbkb 503 Ikbkb negatively regulates the anti-hypertrophic action of Irf7/Nf-kappa B in pathological
hypertrophy
TAC, Pe, AngII (53, 54)
Ptk2/Fak 379 Reduced levels of Ptk2 were accompanied by prevention, as well as reversal, of load-
induced LV hypertrophy
TAC (55)
Rapgef3 539, 721 KO reduces β-adrenergic stimulation-induced hypertrophy TAC (56)
Rheb 141 Rheb activates mTORC1 signaling-dependent hypertrophy TAC, MI (57)
Tln1 124, 503 Reduction of Tln1 expression improves cardiac remodeling TAC (58)
UPREGULATEDTARGET MRNA INVOLVED IN PHYSIOLOGICAL HYPERTROPHY
Akt 302 Increased Akt is involved in physiological hypertrophy MI, Ex (16, 59, 60)
Prkcd 181c Prkcd activates non-pathological hypertrophy MI (61)
DOWNREGULATEDTARGET MRNA INVOLVED IN PHYSIOLOGICAL HYPERTROPHY
Ctnnb1 141 Down regulation is required for adaptive remodeling AngII (62)
Pik3ca 124 Constitutively active Pik3ca/p110α increases the hypertrophic response in TAC;, is
activated in physiological hypertrophy
TAC, Ex (63, 64)
Pla2g4a 543 Hypertrophic growth is increased in Pla2g4a−/− in TAC; increasing Igf-1 TAC (65)
IPA and additional literature were used to evaluate the role of 27 bona fide target mRNAs in the development of cardiac hypertrophy (see Figure 4). Twenty of the
initial 27 target mRNAs were shown to be validated in mouse models for cardiac hypertrophy, as indicated in the table, together with the relevant literature and
description of the principal findings. These models included transverse (ascending) aortic constriction (TAC), LV remodeling following myocardial infarction (MI), and
Angiotensin II (AngII), isoproterenol (Iso), and phenylephrine (Pe) induced pathological hypertrophy, and exercise (Ex) induced physiological hypertrophy.The identified
T3-regulated miRNAs are depicted in green (reduced expression) or red (increased expression). The direction of change of the predicted target mRNAs is similarly
color coded. Fifteen target mRNAs are predicted to be regulated by the indicated miRNAs in such a way that pathological signaling is suppressed. For example,
Map2k3 has been shown in aTAC model to suppress pathological remodeling. Consequently, its upregulation by decreased miR-590 expression is considered to limit
pathological signaling. Likewise, Camk2d is required for TAC-induced pathological remodeling and its suppression by the upregulated miRNAs 539 and 7b is again
considered to limit pathological signaling. The remaining five target mRNAs are regulated in such a way that physiological signaling is enhanced.
formed a miRNA signature unique for short-term T3 treatment
in the LV. To test for potential target mRNAs, in silico target
prediction was performed using IPA. Thirty-one of the 52 had
targeting information available in the database, resulting in 3274
confirmed or highly predicted targets. Core analysis included in
IPA was used to interpret the target mRNA data in the context of
biological functions and processes. Besides “cardiovascular system
development and function,” processes in which target mRNAs are
known to be involved included “cell death and survival,” “cellular
growth and proliferation,”“energy metabolism,” and “lipid metab-
olism.” These findings are in accordance with the concept that TH
plays a determining role in cell proliferation, differentiation, and
metabolism (74, 75).
Next, the analysis was limited to target mRNAs that were solely
targeted by either up- or downregulated miRNAs, so that the
effect of miRNA regulation on the expression of these signaling
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components was unequivocal, resulting in 2312 target mRNAs.
Subsequently, we searched for target mRNAs involved in car-
diac hypertrophy pathways. Signature cardiac hypertrophy path-
ways, such as IGF-1-, PI3K/Akt-, JAK/STAT-, and TH-signaling
pathways, are mostly associated with physiological hypertrophy,
whereas GPCR-, Ca2+-, ERK/MAPK-, and NFAT signaling path-
ways are associated with pathological hypertrophy (16). Analysis
revealed 27 target mRNAs that were indicated by IPA to be part
of at least one of the signature pathways mentioned above and
have been validated in models of pathological and/or physiological
hypertrophy. In the setting of T3-induced hypertrophy, the pre-
dicted regulation of 19% of these targets indicates enhancement
of physiological hypertrophy, while 56% indicates suppression of
pathological remodeling.
For instance, Hif1α and Camk2d are upregulated in both
human and mouse pathological hypertrophy (51, 76). Inactivation
of Hif1α in TAC mouse models resulted in a beneficial effect pre-
venting cardiac growth (51, 77). Transgenic mouse models overex-
pressingCamk2d, the predominant isoform expressed in the heart,
established the involvement of Camk2d in pathological hypertro-
phy (78). Specific inhibition of Camk2d attenuated cardiac growth
in response to several hypertrophic stimuli (44, 45, 79). It was con-
sequently suggested that target-specific inhibition of Camk2d may
be a useful treatment of cardiac hypertrophy (80). Another exam-
ple is connective tissue growth factor, Ctgf, which in the present
study is targeted by three upregulated miRNAs, miR-212, 124, and
18a, suggesting a strong downregulation. It has been reported that
while the initial overexpression of Ctgf activates Akt, triggering
adaptive hypertrophy, the prolonged Ctgf overexpression eventu-
ally leads to heart failure (46, 81). These, and other target mRNAs
listed in Table 2 are predicted by IPA to be downregulated by T3-
dependent miRNAs, suggesting that fine-tuning by these miRNAs
attenuates the development of pathological hypertrophy.
Likewise, it has been described that increased expression of
the serine/threonine kinase Akt results in cell growth (82), both in
pathological and in physiological hypertrophy (83). Recent studies
using Akt knockout mouse models suggest that Akt is more likely
to be required for physiological hypertrophy than for pathological
hypertrophy (59). It has been shown that short-term activation
of Akt is associated with cardiac protection (84), utilization of
glucose, instead of free fatty acids, and improvement of cardiac
contractility (85). For Ctnnb1/Beta-catenin, a key molecule in
pathways associated with cardiac hypertrophy, it has been shown
that decreased expression levels are important for the process of
adaptive left ventricular remodeling (62), suggesting that the pre-
dicted fine-tuning of these target mRNAs enhances physiological
hypertrophy.
Although we limited our analyses to miRNAs that were strongly
responsive to T3 treatment, and to target mRNAs that have been
validated in mouse models, future studies should be aimed at
confirming the predicted regulation of the target mRNAs and
their proteins. At present, our data suggest that cardiac T3-action
includes a novel level of regulation in which a unique set of
T3-dependent miRNAs enhances some aspects of physiological
hypertrophy, but primarily suppresses pathological hypertrophic
signaling. This suggests a mechanism that may in part explain why
cardiac hypertrophy due to high circulating T3 levels does not
progress to dysfunction, in spite of the chronic hemodynamic over-
load, which in the context of cardiovascular disease is the principal
trigger of pathological hypertrophy (10). This proposed mecha-
nism may be relevant for our understanding of the progression
of adverse remodeling. As in other severe illnesses, heart failure is
often associated with reduced plasma T3 levels, the so-called non-
thyroidal illness syndrome (86). Clinical studies have shown that
the extent of the reduction is an independent predictor of mortal-
ity in patients with chronic heart failure (87, 88). In addition, we
and others have shown that increased cardiac activity of the TH
inactivating enzyme,Dio3, results in a local hypothyroid condition
in the pathologically remodeled heart due to pressure overload or
following myocardial infarction (38, 89, 90). Indeed, alterations
in gene expression in the failing heart are to some extent similar
to the genetic profile of a hypothyroid heart (4). Taken together,
this suggests that reduced T3-signaling in the hemodynamically
overloaded heart will aggravate adverse remodeling by releasing
the T3-dependent miRNA brake on these pathological signaling
pathways. Manipulation of these miRNAs may be an additional
option in the ongoing development of miRNA-based therapeutics
for the treatment of heart failure (91, 92).
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